StemCell Therapy

Treatment of Caviar, Gold and Stem cells with Dr.Nader Saab - part 1
A mixture of stem cells and caviar and gold with Dr. Nader Saab on ORBIT TV - #1605; #1586; #1610; #1580; #1575; #1604; #1582; #1604; #1575; #1610; #1575; #1575; #1604; #1580; #1584; #1593; #1610; #1577; #1608; #1575; #1604; #1603; #1575; #1601; #1610; #1575; #1585; #1608; #1575; #1604; #1584; #1607; #1576; #1605; #1593; #1583;. #1606; #1575; #1583; #1585; #1589; #1593; #1576; #1593; #1604; #1609; #1602; #1606; #1575; #1577; #1571; #1608; #1585; #1576; #1578; #1601; #1610; #1593; #1610; #1608; #1606; #1576; #1610; #1585; #1608; #1578;

By: NaderSaab

Go here to read the rest:
Treatment of Caviar, Gold and Stem cells with Dr.Nader Saab - part 1 - Video

Jorge Paz MD: Adult Stem Cell Therapy for Arthritis, Sports Injury, and Autoimmune Disease || 3 of 3
Stem cell therapy for osteoarthritis using adipose (fat) stem cell. Case study of 76 year-old man with osteoarthritis in his knees. Stromal vasular fraction treatment statistics including side effects collected over 800 infusions. Stem cell treatments for sports injuries and why pro sports stars are seeking treatment. Case study of a professional dancer with knee and neck problems who returned to competition after stem cell treatment in Panama.

By: cellmedicine

Link:
Jorge Paz MD: Adult Stem Cell Therapy for Arthritis, Sports Injury, and Autoimmune Disease || 3 of 3 - Video

By JENNY F. MANONGDO

Manila, Philippines Doctors yesterday warned against fatal complications of the use of stem cell therapy.

According to the Philippine Society for Stem Cell Medicine (PSSCM), a stem cell transplant poses a host of complications, including fatal complications that depend on several factors such as the type of blood disorder, type of transplant and the age and health of the person receiving the transplant. If the stem cell that you received is not from your own body, it could lead to fatal complications, PSSCM said.

The Philippine Medical Association (PMA) also warned that a patients body may reject the transplant stem cells from a donor.

Although some people experience few problems with a transplant, others may develop complications that may require treatment or hospitalization. Some complications could even be life-threatening, said Dr. Leo Olarte, PMA vice-president.

According to Olarte, the complications that can arise with a stem cell transplant include graftversus-host disease, stem cell (graft) failure, organ injury, infections, cataracts, infertility, new cancers, and even death.

According to Olarte, a person who will undergo a stem cell transplant from a donor (allogeneic stem cell transplant) may be at risk of graft-versus-host disease.

This condition occurs when a donors transplanted stem cells attack your body. Graft-versushost disease can be mild or severe. It can occur soon after your transplant or months to years later. Aside from the graft-versushost disease, stem cell transplant from a donor can likewise affect any organ, commonly the skin (rash, often like sunburn), gut (mouth sores, abdominal pain, diarrhea, nausea or vomiting), liver (jaundice or yellowing of the skin), lungs (blocked airways) or eyes (irritation and light sensitivity).

Olarte said it could also lead to chronic disability arising from organ injury or infections that are potentially life-threatening.

Commercial establishments offering stem cell treatments have increased following its popularity in the treatment of various diseases.

See original here:
DOH: Stem cell therapy dangerous

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/4gllbg/cell_therapy) has announced the addition of Jain PharmaBiotech's new report "Cell Therapy - Technologies, Markets and Companies" to their offering.

This report describes and evaluates cell therapy technologies and methods, which have already started to play an important role in the practice of medicine. Hematopoietic stem cell transplantation is replacing the old fashioned bone marrow transplants. Role of cells in drug discovery is also described. Cell therapy is bound to become a part of medical practice.

Stem cells are discussed in detail in one chapter. Some light is thrown on the current controversy of embryonic sources of stem cells and comparison with adult sources. Other sources of stem cells such as the placenta, cord blood and fat removed by liposuction are also discussed. Stem cells can also be genetically modified prior to transplantation.

Cell therapy technologies overlap with those of gene therapy, cancer vaccines, drug delivery, tissue engineering and regenerative medicine. Pharmaceutical applications of stem cells including those in drug discovery are also described. Various types of cells used, methods of preparation and culture, encapsulation and genetic engineering of cells are discussed. Sources of cells, both human and animal (xenotransplantation) are discussed. Methods of delivery of cell therapy range from injections to surgical implantation using special devices.

Cell therapy has applications in a large number of disorders. The most important are diseases of the nervous system and cancer which are the topics for separate chapters. Other applications include cardiac disorders (myocardial infarction and heart failure), diabetes mellitus, diseases of bones and joints, genetic disorders, and wounds of the skin and soft tissues.

Regulatory and ethical issues involving cell therapy are important and are discussed. Current political debate on the use of stem cells from embryonic sources (hESCs) is also presented. Safety is an essential consideration of any new therapy and regulations for cell therapy are those for biological preparations.

The cell-based markets was analyzed for 2012, and projected to 2022.The markets are analyzed according to therapeutic categories, technologies and geographical areas. The largest expansion will be in diseases of the central nervous system, cancer and cardiovascular disorders. Skin and soft tissue repair as well as diabetes mellitus will be other major markets.

The number of companies involved in cell therapy has increased remarkably during the past few years. More than 500 companies have been identified to be involved in cell therapy and 285 of these are profiled in part II of the report along with tabulation of 272 alliances. Of these companies, 156 are involved in stem cells. Profiles of 70 academic institutions in the US involved in cell therapy are also included in part II along with their commercial collaborations. The text is supplemented with 55 Tables and 11 Figures. The bibliography contains 1,050 selected references, which are cited in the text.

Key Topics Covered:

See the original post here:
Research and Markets: Cell Therapy - Technologies, Markets and Companies - 2013 Report

Method to derive stem cells
Method allow for an efficient derivation of Embryonic Stem Cells (ESC) to be used in cell therapy.

By: ParcRecercaUAB

More:
Method to derive stem cells - Video

AUSTIN, Texas, Jan. 8, 2013 /PRNewswire/ --On Friday, January 4th Celling Biosciences hosted the Austin Cell Therapy Symposium at the downtown Hilton to build awareness and provide a platform for physicians, scientists, policy makers and academia to discuss the impact of cell therapy on global healthcare and the opportunity for the local community in Central Texas. Cell therapy will revolutionize the landscape of medicine by providing viable and affordable treatment options across all disciplines of medicine without the controversy associated with embryonic stem cells.

The keynote speaker for the event was Dr. Arnold I. Caplan, Professor of Biology and Director of the Skeletal Research Center at Case Western Reserve University. Dr. Caplan has published over 390 papers and manuscripts and has long been supported by the National Institute of Health and other non-profit and for-profit agencies for his efforts in trying to understand the development, maturation and aging of cartilage, bone, skin and other mesenchymal cell tissues."I firmly believe that the research and development efforts going on today will change the future of medicine forever. We are only scratching the surface of the potential there is to treat different health issues with cell therapy. It takes a concerted effort by scientists, physicians and commercial entities for patients to ultimately enjoy the benefits. This type of platform provided by Celling Biosciences allows us to effectively progress forward," says Dr. Caplan.

Dr. Carl Gregory from the Texas A&M Regenerative Medicine Institute and Dr. Vivienne Rebel from UT Health Science Center San Antonio both represented local academia in Central Texas. The research being conducted and the recruitment of students trained in these programs are obvious reasons for Texans to keep supporting Governor Perry's efforts to make Texas a leader in the research and commercialization efforts of regenerative cell therapy. Both speakers are leading efforts for research that will one day lead to alternative healthcare options.

Dr. Philippe Hernigou, a leading orthopedic surgeon from France, presented his 20 years clinical experience working with cell therapy in his practice as University of Paris Chief of Orthopedics.Dr. Hernigou is well published in his clinical use of cell therapy and has treated over 2,500 patients utilizing autologous bone marrow derived cells to treat a wide range of orthopedic pathologies. Dr. Hernigou's research on the safety of cell therapy has been accepted and will be presented at the 2013 AAOS, a leading congress for orthopedic surgeons.

Clinicians were also represented by Dr. Scott Spann, an orthopedic surgeon at Westlake Hospital in Austin, who provides care to patients with spinal cord injury.Dr. Spann believes one day cell therapy will be a common option for patients suffering from debilitating health issues like spinal cord injury.A member of the audience and orthopedic surgeon, Dr. Christoph Meyer has been utilizing cell therapy in his practice for years and also believes it is the future of medicine. "Thanks to these efforts, physicians are benefiting from access to the growing body of research based medicine being established in the field of cellular therapy and regenerative medicine.As the technology is developed, it ultimately gives my patients the best care available and this event gives me the opportunity to discuss experiences with world leaders in cell therapy."

Healthcare is going through major changes and cell therapy is going to have many challenges ahead. Julian Rivera, legal healthcare specialist at the Brown McCarroll Law Firm, discussed the impact of the recent challenges in front of the Texas Medical Board which has adopted rules that work with the FDA to help keep Texas revolutionizing cell therapy.Mr. Rivera believes that the legal issues will take time but is optimistic about how the State of Texas has handled the challenges thus far.

"We are fortunate to have industry leaders joining us to discuss the future impact of cell therapy. We are proud to be Texans who are pioneering the way in the global healthcare market place for regenerative cell therapies. Celling Biosciences understands that the cell therapy market is in its infancy which is a key reason why we invest heavily on research and development with our teams of scientists, engineers and registered nurses providing physicians with proven cell centric technologies and techniques that collectively help to recreate the human body's biological environment. It is not about just providing cells to treat patients.We believe with the help of these thought leaders presenting today we will get closer to better understanding how to keep delivering safe, efficacious and cost effective therapies to patients," says Founder and CEO of Celling Biosciences, Kevin Dunworth.

About Celling BiosciencesCelling Biosciences is an Austin based company working closely with world leaders in academia, medicine, scientists and engineers to research and develop innovative technologies in the emerging field of regenerative medicine.Celling's product-offering focuses on autologous adult stem cell therapy and the devices and services that compliment these procedures.For more information please visit: http://www.cellingbiosciences.com.

See original here:
Celling Biosciences Hosts Austin Cell Therapy Symposium

REHOBOTH, Mass. --

A first of its kind procedure is being performed in Massachusetts Monday. Its a stem cell therapy on a dog.

"He can't get comfortable, can't lay down, because of the pain, so he sits up and stares at the wall all night, which is tough to watch," said Bob Cook, Bubbas owner.

Cook of Taunton is talking about his 2-year-old English Bulldog Bubba, who suffers from hip dysplasia.

He said his condition has gotten worse in the last several months. After doing research, he found out about a regenerative stem cell therapy and has been hopeful.

He brought Bubba to the Abbot Animal Hospital in Rehoboth.

"Hopefully we can give these animals relief and increase quality of life and their life span as well, said Dr. Ashraf Gomaa.

Gomaa is the only doctor in our area certified by MediVet America, the company that developed this technology.

After extracting fat from Bubba, it is processed in a machine that basically breaks down the cells to get to the healthy stem cells. The cells are then injected back into Bubba into the area of concern.

"Replacing the bad cells with new cells, pretty advanced technology," Gomaa said.

Continued here:
Owner hopes stem cell therapy will get dog's life back

AMSTERDAM, January 7, 2013 /PRNewswire/ --

Official journal of the International Society for Cellular Therapy (ISCT) to be published by Elsevier beginning January 2013

Elsevier, a world-leading provider of scientific, technical and medical information products and services, is pleased to announce that the International Society for Cellular Therapy (ISCT) has selected Elsevier to publish Cytotherapy: The Journal of Cell Therapy effective January 2013.

"Elsevier presented ISCT with unsurpassed reach into the global medical community, top class publishing services, and significant experience in this field. We are extremely confident that our collaboration with Elsevier will not only help Cytotherapy grow for the benefit of our members and readers, but also for the benefit of all scientists, technologists, regulators, manufacturing experts and others dedicated to translational development of safe and effective cell therapies," said ISCT President, Kurt Gunter, MD, FASCP.

Cytotherapy is a highly influential publication in the mainstream of the rapidly expanding field of cell-based treatments for cancer, degenerative disorders, immunotherapy and stem cell transplantation. Cytotherapy publishes cutting edge findings, clinical trials of cell-based therapies, and news and opinion on all aspects of these disciplines. The journal focuses especially on the practical translation of scientific developments in the laboratory into clinical practice. Cytotherapy is an essential global resource for clinical researchers, oncologists, hematologists, doctors, and regulatory experts involved in cell processing and therapy.

Senior Editor of Cytotherapy, John Barrett, MD, commented, "What matters is ensuring that new peer-reviewed treatments, developments, and studies reach as many specialists working with cell therapies as possible. In this, I believe Elsevier offers an unrivaled opportunity to help the journal achieve this goal."

Glen Campbell, Executive Vice President at Elsevier added, "Cytotherapy is an established and reputable journal and we are honored that the International Society for Cellular Therapy selected Elsevier as their publishing partner. Together, we will ensure that this prestigious title develops further as the leading global forum and resource for developing and supporting innovative cellular therapies."

For more information go to: http://www.journals.elsevier.com/cytotherapy

About ISCT

ISCT is a global association driving the translation of scientific research to deliver innovative cellular therapies to patients. Since 1992, ISCT has been the leading global forum for developing and supporting innovative cellular therapies through communication, education and training. ISCT fosters international translational research, informs national and global regulatory framework development and harmonization, drives commercialization strategies, and educates principal investigators, lab directors, technologists, regulators and commercial stakeholders. http://www.celltherapysociety.org

See the article here:
Elsevier Selected to Publish Cytotherapy: The Journal of Cell Therapy

SUNRISE, Fla., Jan. 7, 2013 /PRNewswire/ --Bioheart, Inc. (BHRT.QB) will present an update on 12 years of clinical data on MyoCell for treating heart failure at the 8th Annual Conference on Cell Therapy for Cardiovascular Disease January 23-25th, 2013 @ Columbia University Medical Center - http://celltherapy.crf.org/register.html - Course Director, Warren Sherman, M.D.

(Logo: http://photos.prnewswire.com/prnh/20130107/FL37699LOGO )

Howard J. Leonhardt, Founder and Chief Technology Officer of Bioheart, will present data from clinical trials sponsored by the company since 2001.

In Phase II/III clinical trials stage in the U.S. for muscle stem cells for treating advanced heart failure, Bioheart's MyoCell is believed to be the only cell type able to create new contractile muscle in heart scar tissue.Phase II/III Part I interim results demonstrated 95.7 meters improvement in exercise capacity in Bioheart MyoCell patients over placebo (-4 meters) in a double blind randomized study.This compares to -4 meters for CHF drugs, 16 meters for CRT pacers, 53 meters for cardiac stem cells, 52 meters for adipose derived cells and 10 meters allogeneic bone marrow derived cells.

Leonhardt will also provide a look at new generation improvements brought forward to enhance cell transplantation by Bioheart which include:SDF-1 gene transfection, electrical stimulation see http://www.myostimpacers.com, repeat injections, and nutrient hydrogel.

Founded in 1999, Bioheart is one of the original cell therapy companies.Since that time, more than 400 heart failure patients have been enrolled in various myoblast therapy clinical trials worldwide. 84% percent of Bioheart MyoCell treated patients have improved while only 16% have worsened. In placebo and control groups 69% of patients have worsened.

130 more patients are needed to complete the randomized, double blinded, placebo controlled MARVEL trial.MyoCell is a muscle-derived stem cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the intended purpose of improving cardiac function and quality of life in chronic heart failure patients.

About Bioheart, Inc.

Bioheart is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Bioheart's goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.

Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit http://www.bioheartinc.com, or visit us on Facebook: Bioheart and Twitter @BioheartInc.

See original here:
Bioheart to Present at Cell Therapy for Cardiovascular Disease Conference in New York

Diamond Before and 30 days after stem cells Treatment for FX. Sesimoid Suspensory Desmitis
Photos before are in clinic are on concrete artificial light The photos 30 days post injection are in natural light on rock surface

By: WichitaEquine

Go here to see the original:
Diamond Before and 30 days after stem cells Treatment for FX. Sesimoid

Stem Cell Therapy for Autism, Mumbai, India

By: Rajeev Ranjan

More here:
Stem Cell Therapy for Autism, Mumbai, India - Video

Source:
http://feedproxy.google.com/~r/CellTherapyBlog/~3/ABphTtPOrwo/cell-therapy-blog-welcomes-2013.html

Source:
http://feedproxy.google.com/~r/CellTherapyBlog/~3/ABphTtPOrwo/cell-therapy-blog-welcomes-2013.html

Jon and tyler embryonic stem cells

By: kiernan4vp

Read the original:
Jon and tyler embryonic stem cells - Video

Carlson second part - blood stem cells
The saga of Carlson 13, the old champion considered clinically irrecoverable, continues. You remember him thin, with scars from the burning and the ultra sound of that tendon lesion that didn #39;t want to heal? You then saw him taking part in his first competitions in December 2011. Today, a year later, how is he? He #39;s totally recovered? You be the judge! Over the year the horse has taken part in many competitions always performing well up to one metre fifty but in November, with my 20 year old daughter Antonia, who this year has taken 8 university exams, he competed in the Celye World Cup one metre sixty competition with only one error. After two weeks Carlson and Antonia reached the fourth place in the Italian Master Memorial Dalla Chiesa, the most important Italian indoor event, with 2 manche without errors where the nearly 17 year old champion made fun of the heights by jumping with a fantastic technique. What #39;s more he did this barefoot. How could this have happened? The blood stem cells that I use in my treatment played a large role. Be aware that stem cells are not a therapeutic protocol in themselves, but are part of the protocol and the better the protocol the better they function. In the scientific work of Dr. Y.Kasashima thoroughbred race horses that had been given bone marrow adult stem cells gave the same performances in competitions 2 years later as did untreated horses left to rest for the same period, even though there was a histological improvement in the ...

By: marcopolettinieng

More here:
Carlson second part - blood stem cells - Video

Cost of Stem Cell Therapy | Malaysia Stem Cell Therapy Cost
stemcellmalaysia.com Stem cell therapy is not a cheap medical treatment. In fact, it is very expensive treatment to the majority of people. The high price of stem cell therapy becomes not only a deterrent to the majority but also creates room for non-medical sector to fill the void of demands for disease treatment. This video addresses the issues surrounding the cost of stem cell therapy, particularly in Malaysia. For more information on stem cell therapy, please visit Stem Cell Malaysia at stemcellmalaysia.com

By: stemcells2012

See original here:
Cost of Stem Cell Therapy | Malaysia Stem Cell Therapy Cost - Video

Targeting Cancer Stem Cells Therapeutic Strategies, Pipeline, Biomarkers and Opportunities

By: Anjali Kalan

Read the rest here:
Targeting Cancer Stem Cells Therapeutic Strategies, Pipeline, Biomarkers and Opportunities - Video

My experience of donating stem cells
A Stem Cell Donor shares her experience and explains why she would go through the whole process again.

By: LeukaemiaCancer

See the original post:
My experience of donating stem cells - Video

Stem Cells Effective in Reversing Dementia
Mary Holler - Angiograms of her cerebral circulation prior to stem cell treatment and then again post treatment.

By: mrcalcat

Follow this link:
Stem Cells Effective in Reversing Dementia - Video

The Promise of Stem Cells
A talk by Dr. Theresa Deisher, President of Sound Choice Pharmaceutical Institute

By: SaintMichaelB

Read this article:
The Promise of Stem Cells - Video